Rechercher des projets européens

5 projets européens trouvés

Recherche sur 125080 projets européens

 TERMINÉ 
Background The core activity of the leather industry has expanded in recent years following the availability of a wider range of dyeing products from dyestuff manufacturers. An estimated 2.3 million tonnes/yr of dyestuff are produced globally. This dyestuff is often chemically complex and heterogeneous in nature, which can present environmental hazard ris ...
Voir le projet

 5

 TERMINÉ 

LSE TECHNOLOGY APPROACH TO GENERATE INNOVATIVE KINASE INHIBITOR DRUGS (LSE)

Date du début: 1 févr. 2013, Date de fin: 31 juil. 2015,

Over the last decade, kinases have emerged as attractive therapeutic targets in inflammatory diseases. Numerous efforts in the pharmaceutical community are directed towards the discovery of small molecule inhibitors that regulate kinase function.A number of issues need to be addressed when considering kinases as targets in inflammation. The combination of efficacy and favourable safety profile is ...
Voir le projet

 6

 TERMINÉ 
Background Chloroparaffin has been widely used in the leather-fatting process owing to its chemical stability, low cost and good performance. Today, however, the requirement to meet high environmental standards means that its use is limited. Chloroparaffin has low biodegradability and a high chlorine content. The EU produces some 150 million m2/year of ca ...
Voir le projet

 5

 TERMINÉ 
"In spite of the substantial erosion of its market share, western Europe (Italy, Spain are respectively first and second producers) still remains the worldwide leader, accounting for 38,9% of the world APIs production and Eastern Europe is growing faster (mainly represented by Hungary). It is then clear that generic APIs represent a strategic industrial field for EU competitiveness, and it is as w ...
Voir le projet

 9

 TERMINÉ 

Innovative multidisciplinary approach to pharma generic production (PHARMAGEN)

Date du début: 1 mai 2009, Date de fin: 30 avr. 2011,

"The motivation of PHARMAGEN stems from a recognition that bulk Active Pharmaceutical Ingredients (API) manufacturers need to employ new synthesis routes and better manufacturing techniques for the manufacture of generics drugs. It is also recognised that a key enabling technology for achieving this goal entails greater use of continuous processes. A successful outcome will deliver processes whic ...
Voir le projet

 9